CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 122 enrolled
Drug / intervention
acetylsalicylic acid +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00474903
NCT00474903Phase 2Completed
CompareCT.gov

Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients

National Cancer Institute (NCI)·interventional·Posted May 17, 2007·Updated Jul 2, 2014

In Brief

A Phase 2 clinical trial evaluating acetylsalicylic acid, esomeprazole magnesium, and 1 other intervention for Barrett Esophagus and Esophageal Cancer. Completed, enrolled 122 participants across 1 site.

Detailed Summary

This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin on tissue PGE2 levels compared with esomeprazole and placebo. This type of chemoprevention treatment investigates the use of certain drugs to assess whether they assist in the prevention of cancer. The use of esomeprazole magnesium with or without aspirin may help prevent esophageal cancer in patients with Barrett esophagus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBarrett Esophagus, Esophageal Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartApr 1, 2007
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 19.1 years ago

Interventions

acetylsalicylic aciddrug

Given orally

esomeprazole magnesiumdrug

Given orally

placeboother

Given orally